Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response

DOI: 10.1371/journal.pone.0210891

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text